While levels of C-reactive protein (CRP) are increasingly used as an inflammation marker for cardiovascular disease, they won’t help predict colorectal cancer risk in women, researchers find.Reporting in the current issue of the Annals of Internal Medicine, investigators at Brigham and Women’s Hospital, in Boston, say their study of more than 27,000 people found that CRP levels were also of no help in predicting increased risks for developing a certain location or stage of colorectal cancer.
